These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 27102360)

  • 1. Selective inhibition of the kinase DYRK1A by targeting its folding process.
    Kii I; Sumida Y; Goto T; Sonamoto R; Okuno Y; Yoshida S; Kato-Sumida T; Koike Y; Abe M; Nonaka Y; Ikura T; Ito N; Shibuya H; Hosoya T; Hagiwara M
    Nat Commun; 2016 Apr; 7():11391. PubMed ID: 27102360
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-activity relationship for the folding intermediate-selective inhibition of DYRK1A.
    Miyazaki Y; Kikuchi M; Umezawa K; Descamps A; Nakamura D; Furuie G; Sumida T; Saito K; Kimura N; Niwa T; Sumida Y; Umehara T; Hosoya T; Kii I
    Eur J Med Chem; 2022 Jan; 227():113948. PubMed ID: 34742017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression and purification of DYRK1A kinase domain in complex with its folding intermediate-selective inhibitor FINDY.
    Kimura N; Saito K; Niwa T; Yamakawa M; Igaue S; Ohkanda J; Hosoya T; Kii I
    Protein Expr Purif; 2022 Aug; 195-196():106089. PubMed ID: 35307559
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanism of dual specificity kinase activity of DYRK1A.
    Walte A; Rüben K; Birner-Gruenberger R; Preisinger C; Bamberg-Lemper S; Hilz N; Bracher F; Becker W
    FEBS J; 2013 Sep; 280(18):4495-511. PubMed ID: 23809146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
    Czarna A; Wang J; Zelencova D; Liu Y; Deng X; Choi HG; Zhang T; Zhou W; Chang JW; Kildalsen H; Seternes OM; Gray NS; Engh RA; Rothweiler U
    J Med Chem; 2018 Sep; 61(17):7560-7572. PubMed ID: 30095246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
    Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
    J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro.
    Adayev T; Chen-Hwang MC; Murakami N; Lee E; Bolton DC; Hwang YW
    Biochemistry; 2007 Jun; 46(25):7614-24. PubMed ID: 17536841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-step virtual screening to develop selective DYRK1A inhibitors.
    Koyama T; Yamaotsu N; Nakagome I; Ozawa SI; Yoshida T; Hayakawa D; Hirono S
    J Mol Graph Model; 2017 Mar; 72():229-239. PubMed ID: 28129593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
    Yoon HR; Balupuri A; Choi KE; Kang NS
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32957634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
    Sonamoto R; Kii I; Koike Y; Sumida Y; Kato-Sumida T; Okuno Y; Hosoya T; Hagiwara M
    Sci Rep; 2015 Aug; 5():12728. PubMed ID: 26234946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.
    Papenfuss M; Lützow S; Wilms G; Babendreyer A; Flaßhoff M; Kunick C; Becker W
    Sci Rep; 2022 Feb; 12(1):2393. PubMed ID: 35165364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation, regulation, and inhibition of DYRK1A.
    Becker W; Sippl W
    FEBS J; 2011 Jan; 278(2):246-56. PubMed ID: 21126318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
    Göckler N; Jofre G; Papadopoulos C; Soppa U; Tejedor FJ; Becker W
    FEBS J; 2009 Nov; 276(21):6324-37. PubMed ID: 19796173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A.
    Falke H; Chaikuad A; Becker A; Loaëc N; Lozach O; Abu Jhaisha S; Becker W; Jones PG; Preu L; Baumann K; Knapp S; Meijer L; Kunick C
    J Med Chem; 2015 Apr; 58(7):3131-43. PubMed ID: 25730262
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
    Mariano M; Hartmann RW; Engel M
    Eur J Med Chem; 2016 Apr; 112():209-216. PubMed ID: 26896709
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A (DYRK1A) Inhibitors as Potential Therapeutics.
    Jarhad DB; Mashelkar KK; Kim HR; Noh M; Jeong LS
    J Med Chem; 2018 Nov; 61(22):9791-9810. PubMed ID: 29985601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
    Zhou Q; Reekie TA; Abbassi RH; Indurthi Venkata D; Font JS; Ryan RM; Munoz L; Kassiou M
    Bioorg Med Chem; 2018 Dec; 26(22):5852-5869. PubMed ID: 30401502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dyrk1a is required for craniofacial development in Xenopus laevis.
    Johnson HK; Wahl SE; Sesay F; Litovchick L; Dickinson AJ
    Dev Biol; 2024 Jul; 511():63-75. PubMed ID: 38621649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway.
    Hong JY; Park JI; Lee M; Muñoz WA; Miller RK; Ji H; Gu D; Ezan J; Sokol SY; McCrea PD
    J Cell Sci; 2012 Feb; 125(Pt 3):561-9. PubMed ID: 22389395
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
    Seifert A; Allan LA; Clarke PR
    FEBS J; 2008 Dec; 275(24):6268-80. PubMed ID: 19016842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.